TW200303213A - Lyophilized monoclonal antibody compositions - Google Patents

Lyophilized monoclonal antibody compositions Download PDF

Info

Publication number
TW200303213A
TW200303213A TW091133319A TW91133319A TW200303213A TW 200303213 A TW200303213 A TW 200303213A TW 091133319 A TW091133319 A TW 091133319A TW 91133319 A TW91133319 A TW 91133319A TW 200303213 A TW200303213 A TW 200303213A
Authority
TW
Taiwan
Prior art keywords
composition
item
antibody
patent application
scope
Prior art date
Application number
TW091133319A
Other languages
English (en)
Chinese (zh)
Inventor
Tracy Chen
Glen Tolman
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of TW200303213A publication Critical patent/TW200303213A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW091133319A 2001-11-09 2002-11-08 Lyophilized monoclonal antibody compositions TW200303213A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34206301P 2001-11-09 2001-11-09

Publications (1)

Publication Number Publication Date
TW200303213A true TW200303213A (en) 2003-09-01

Family

ID=23340162

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091133319A TW200303213A (en) 2001-11-09 2002-11-08 Lyophilized monoclonal antibody compositions

Country Status (7)

Country Link
EP (1) EP1455822A4 (de)
JP (1) JP2005508992A (de)
AR (1) AR037304A1 (de)
CA (1) CA2466641A1 (de)
MX (1) MXPA04004459A (de)
TW (1) TW200303213A (de)
WO (1) WO2003041637A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6982080B2 (en) 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
JP2012511531A (ja) * 2008-12-09 2012-05-24 エフ．ホフマン−ラ ロシュ アーゲー 賦形剤不含抗体溶液を得るための方法
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
EP3111954B1 (de) 2010-11-05 2019-04-03 Novartis Ag Verfahren zur behandlung von spondylitis ankylosans mit anti-il-17 antikörpern
AU2018334502A1 (en) 2017-09-15 2020-03-12 Amgen Inc. Process for lyophilized pharmaceutical formulation of a therapeutic protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4891319A (en) * 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
AU2309692A (en) * 1991-07-03 1993-02-11 Cryolife, Inc. Method for stabilization of biomaterials
CA2128527A1 (en) * 1992-01-21 1993-07-22 Raymond P. Goodrich, Jr. Method of freezing cells and cell-like materials
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL122482A (en) * 1995-06-07 1999-10-28 Quadrant Holdings Cambridge Methods for stably incorporating substances within dry foamed glass matrices and compositions obtained thereby
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
EP1345968A2 (de) * 2000-12-28 2003-09-24 Altus Biologics Inc. Kristalle ganzer antikörper und fragmente davon und verfahren zu ihrer herstellung und verwendung

Also Published As

Publication number Publication date
EP1455822A2 (de) 2004-09-15
EP1455822A4 (de) 2004-12-29
MXPA04004459A (es) 2005-05-16
WO2003041637A3 (en) 2004-01-22
AR037304A1 (es) 2004-11-03
WO2003041637A2 (en) 2003-05-22
CA2466641A1 (en) 2003-05-22
JP2005508992A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
CN106999591B (zh) 一种抗pd-1抗体制剂及其在医药上的应用
CA2272245C (en) Stable lyophilized pharmaceutical preparations of monoclonal or polyclonal antibodies
AU2013255413C1 (en) Pharmaceutical formulations of TNF-alpha antibodies
CN1886158B (zh) 包含抗egf受体抗体的药物制剂
ES2897500T3 (es) Formulaciones de anticuerpos T1h
CA2037884C (en) Stabilized gonadotropin containing preparations
BRPI0710508A2 (pt) composição de pepticorpo terapêutico liofilizado, métodos para fabricar um papticorpo terapêutico liofilizado e para preparar uma composição de pepticorpo terapêutico liofilizado e para preparar uma composição farmacêutica aquosa
KR20110085917A (ko) 지속형 과립구 콜로니 자극인자 결합체의 액상 제제
JP6761015B2 (ja) 弱毒生アルファウイルス製剤のための組成物および方法
EA032336B1 (ru) Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
TW200303213A (en) Lyophilized monoclonal antibody compositions
AU2002337895A1 (en) Lyophilized monoclonal antibody compositions
WO2016059593A1 (en) Stable injectable composition of protein drugs and process for its preparation
JP2023553106A (ja) 改善された凍結乾燥製剤
BRPI9715268B1 (pt) preparações farmacêuticas liofilizadas estáveis de anticorpos monoclonais ou policlonais, bem como processo para sua produção
EP2727584A1 (de) Abgase zur Verwendung beim Trocknen, Lagern bzw. Rekonstituieren von Biomolekülen